27,056 AstraZeneca Plc $AZN Shares Acquired by International Assets Investment Management LLC

Key Points

• International Assets Investment Management LLC increased its AstraZeneca stake by 1,564.8%, purchasing 27,056 additional shares to own 28,785 shares worth approximately $4.65 million. Institutional investors collectively own 20.35% of the company.
• AstraZeneca reported a strong third quarter, with EPS of $2.79 and revenue of $16.21 billion beating estimates; oncology sales rose 17% and management reaffirmed its 2026 growth outlook.
• The company’s long-term prospects are supported by more than $20 billion in potential from 2027 trial readouts, though generic competition affecting mature products such as Farxiga remains a headwind. Analysts maintain a “Moderate Buy” consensus with an average price target of $206.67.

International Assets Investment Management LLC boosted its stake in AstraZeneca Plc (NYSE:AZN - Free Report) by 1,564.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 28,785 shares of the company's stock after purchasing an additional 27,056 shares during the period. International Assets Investment Management LLC's holdings in AstraZeneca were worth $4,648,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Mascoma Wealth Management LLC purchased a new position in shares of AstraZeneca during the first quarter worth $26,000. Roxbury Financial LLC purchased a new stake in shares of AstraZeneca in the 2nd quarter valued at $29,000. Resources Management Corp CT ADV purchased a new stake in shares of AstraZeneca in the 1st quarter valued at $35,000. Allied Private Wealth LLC purchased a new stake in shares of AstraZeneca in the 2nd quarter valued at $35,000. Finally, Laurel Wealth Advisors LLC acquired a new position in AstraZeneca during the 3rd quarter worth about $30,000. Institutional investors and hedge funds own 20.35% of the company's stock.

Key Headlines Impacting AstraZeneca

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Q3 earnings beat expectations: Core EPS reached $2.79 versus the roughly $2.60 analyst consensus, while revenue increased about 7% year over year to $16.21 billion, topping estimates near $16 billion. Net profit rose to $3.12 billion from $2.54 billion a year earlier. AstraZeneca Stock Rallies on Q3 Earnings Beat
• Positive Sentiment: Oncology remains the key growth engine: Cancer-drug sales rose 17%, helping offset generic competition and declining sales from mature medicines such as Farxiga. The performance suggests AstraZeneca’s newer products are mitigating patent-cliff pressure. AZN Q3 Earnings Beat Estimates
• Positive Sentiment: Pipeline catalysts support the longer-term story: Management highlighted more than $20 billion of potential from 2027 drug-trial readouts, while the company reported 12 positive Phase 3 readouts. These catalysts could expand AstraZeneca’s growth prospects beyond its current portfolio. AstraZeneca CEO Sees Over $20B Potential
• Positive Sentiment: Guidance was reaffirmed: AstraZeneca maintained its fiscal 2026 outlook for mid-to-high single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates. The company also targeted $1.5 billion in annual savings, potentially supporting margins and earnings. AstraZeneca Reports Q3 Revenue Growth
• Neutral Sentiment: Analyst views remain mixed: Guggenheim maintained a Buy rating, while Deutsche Bank retained Hold and Erste Group Bank lowered its FY2026 EPS estimate, indicating some valuation and execution concerns remain. Guggenheim Maintains Buy Rating
• Negative Sentiment: Generic competition remains a headwind: Farxiga and other mature products face pricing and volume pressure, which could limit growth if newer oncology and pipeline medicines do not continue to scale. AstraZeneca Holds Guidance

AstraZeneca Price Performance

Shares of NYSE AZN opened at $186.49 on Monday. The stock's 50-day simple moving average is $164.48 and its 200-day simple moving average is $180.21. The firm has a market capitalization of $289.23 billion, a PE ratio of 26.38, a price-to-earnings-growth ratio of 1.45 and a beta of 0.24. AstraZeneca Plc has a fifty-two week low of $153.41 and a fifty-two week high of $212.71. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89.

AstraZeneca (NYSE:AZN - Get Free Report) last posted its earnings results on Friday, October 30th. The company reported $2.79 EPS for the quarter, beating analysts' consensus estimates of $2.60 by $0.19. AstraZeneca had a net margin of 17.68% and a return on equity of 32.34%. The firm had revenue of $16.21 billion for the quarter, compared to the consensus estimate of $16 billion. During the same period last year, the firm posted $2.38 EPS. The company's revenue was up 6.5% on a year-over-year basis. As a group, equities research analysts forecast that AstraZeneca Plc will post 10.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Citigroup restated a "buy" rating on shares of AstraZeneca in a report on Tuesday, October 6th. Nordea Equity Research upgraded shares of AstraZeneca from a "sell" rating to a "buy" rating in a research note on Tuesday, October 13th. Wall Street Zen raised shares of AstraZeneca from a "hold" rating to a "buy" rating in a research report on Saturday. Zacks Research raised shares of AstraZeneca from a "strong sell" rating to a "hold" rating in a research note on Tuesday, October 13th. Finally, HSBC lowered shares of AstraZeneca from a "buy" rating to a "hold" rating in a research note on Monday, July 13th. Sixteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, AstraZeneca presently has a consensus rating of "Moderate Buy" and an average price target of $206.67.

AstraZeneca Company Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.